Drug
Oxymorphone
Oxymorphone: highest development phase Phase 3, developed by Endo. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Endo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Oxymorphone ER NCT00765856 | Phase 3 | Chronic Pain |
| oxymorphone IR NCT01206907 | Phase 3 | Chronic Pain |
| oxymorphone HCl NCT01210352 | Phase 3 | Post Operative Pain |
| Oxymorphone ER NCT00945919 | Not Applicable | Chronic Nociceptive Pain |
Latest
No recent events.
Follow Oxymorphone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.